A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multi-Center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder

Next Previous
Trial Profile

A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multi-Center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Acronyms SCORPIO
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 15 Apr 2014 Pooled results for urinary retention rates presented at the 29th Congress of the European Association of Urology.
    • 08 May 2013 Tolerability results from a pooled analysis presented at the 108th Annual Meeting of the American Urological Association.
    • 08 May 2013 Pooled efficacy analysis presented at the 108th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top